EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Unraveling the meta-hallmarks between senescent and tumor cells: A new perspective for senolytic drug discovery

Wei Liu, Bo Fan, Te Fang, Hongyao Li, Jin Zhang, Bo Liu, Zhiyu Liu

Acta Pharmaceutica Sinica B · 2025-10 · 15 (10) · 5071-5098

DOI: 10.1016/j.apsb.2025.08.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2025-10. Verfasst von Wei Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 266 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aging and cancer share overlapping characteristics, referred to as meta-hallmarks, which elucidate the convergent, antagonistic, or contradictory relationships between aging and cancer. Likewise, as a key characteristic of aging, senescent cells share some meta-hallmarks with tumor cells. These hallmarks include apoptosis resistance, metabolic alterations, secretory phenotypes, epigenetic reprogramming, and immune surveillance, all of which play pivotal roles in both tumorigenesis and senescence. Moreover, senolytic drugs, which are a class of agents selectively designed to eliminate senescent cells, have emerged as promising therapeutic agents in oncology and aging-related diseases. Since the discovery of the first senolytic drug in 2015, a diverse array of such agents has been developed. Notably, most senolytic drugs are repurposed from existing anti-tumor therapies, leveraging their shared mechanisms with senescent cells and tumor cells. Thus, this review examines the similarities between senescent cells and tumor cells, providing a better understanding of the meta-hallmarks. Besides, we categorize existing senolytic drugs based upon meta-hallmarks and elucidate the potential molecular mechanisms underlying their effects. By integrating insights from cancer and senescence research, this work aims to inspire innovative strategies for senolytic drug discovery.

Schlagwörter

Stichwörter der Autor:innen

Anti-tumor drugCancerCell senescenceDrug discoveryMeta-hallmarkRepurposingSenolytic drugSenolytic therapy

Autor:innen und Institutionen

  • Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
  • Department of Urology, Institute of Precision Drug Innovation and Cancer Center, Second Affiliated Hospital of Dalian Medical University, Dalian 116023, China.
  • Department of Anesthesiology, the First Affiliated Hospital of China Medical University, Shenyang 110001, China.
  • School of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518060, China.

Zitieren

APA

Liu, W., Fan, B., Fang, T., Li, H., Zhang, J., Liu, B., & Liu, Z. (2025). Unraveling the meta-hallmarks between senescent and tumor cells: A new perspective for senolytic drug discovery. Acta Pharmaceutica Sinica B, 15(10), 5071-5098. https://doi.org/10.1016/j.apsb.2025.08.010

Vancouver

Liu W, Fan B, Fang T, Li H, Zhang J, Liu B, et al. Unraveling the meta-hallmarks between senescent and tumor cells: A new perspective for senolytic drug discovery. Acta Pharmaceutica Sinica B. 2025;15(10):5071-5098. doi:10.1016/j.apsb.2025.08.010

BibTeX
@article{Liu2025,
  author = {Liu, Wei and Fan, Bo and Fang, Te and Li, Hongyao and Zhang, Jin and Liu, Bo and Liu, Zhiyu},
  title = {Unraveling the meta-hallmarks between senescent and tumor cells: A new perspective for senolytic drug discovery},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2025},
  volume = {15},
  number = {10},
  pages = {5071--5098},
  doi = {10.1016/j.apsb.2025.08.010}
}
Kostenlos starten →